This study is investigating how a dietary supplement called GlyNAC, which combines glycine and N-acetylcysteine, might help people with Alzheimer's disease. Researchers believe that problems with brain energy use, inflammation, and insulin resistance are linked to Alzheimer's. This trial will compare GlyNAC to a placebo (alanine) to see if it improves these issues and also affects your thinking and memory (cognition). To join, you must be between 55 and 85 years old, have memory loss for over a year with a specific cognitive score, and have a positive amyloid PET scan (a brain scan that checks for a protein linked to Alzheimer's). The study is currently unclear on its recruitment status and plans to enroll 52 participants.

Study design

This is an interventional study comparing GlyNAC to a placebo, with a planned enrollment of 52 participants.

What's involved

You would undergo imaging studies (MRI, FDG-PET, and TSPO-PET scans) before starting supplementation, and FDG- and TSPO-PET scans would be repeated after 24 weeks. Cognitive and metabolic measurements will be taken before supplementation, and after 12 and 24 weeks.

Compensation

Not stated in the trial record.

Follow-up

Cognition, brain glucose uptake, and brain inflammation will be measured up to 24 weeks after starting supplementation.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.